NCCN Releases New Guidance on COVID-19 Vaccine for Patients with Cancer
FDA Approves Fam-Trastuzumab Deruxtecan-Nxki for Adenocarcinoma
CMS Releases C-Code for Belantamab Mafodotin-blmf
FDA Approves Osimertinib for the Adjuvant Treatment of EGFRm NSCLC
FDA Approves Relugolix for Advanced Prostate Cancer
FDA Approves Selinexor for R/R Multiple Myeloma
FDA Issues EUA for Moderna's COVID-19 Vaccine
FDA Approves Amgen's Rituximab Biosimilar
FDA Approves Margetuximab for Patients with Metastatic HER2+ Breast Cancer
FDA Issues EUA for First COVID-19 Vaccine
CMS Announces RO Model Updates
FDA Approves Pralsetinib for RET-Altered Thyroid Cancers
FDA Approves PSMA-Targeted PET Imaging Drug for Prostate Cancer
Moderna Announces EUA Request to FDA for COVID-19 Vaccine Candidate
CMS Announces Resources + Office Hours for RO Model Participants
CMS Issues Most Favored Nation Drug Pricing Model
FDA Issues EUA for Casirivamab + Imdevimab Antibodies to Treat COVID-19
Pfizer + BioNTech Announce EUA Request to FDA for COVID-19 Vaccine
CMS Announces Quality Payment Program COVID-19 Exception Application
FDA Approves Pembrolizumab + Chemotherapy for TNBC
CMS Reminder to Update Billing Information to Receive APM Incentive Payments
CMS Announces 2021 Federal Health Insuance Exchange Open Enrollment Period
CMS Announces Radiation Oncology Model Delay
FDA Approves Venetoclax in Combination for Untreated AML
Immunomedics Announces New C-Code for Trodelvy™, Effective October 2020
FDA Approves Expanded Indication of Pembrolizumab for R/R cHL
FDA Approves Nivolumab + Ipilimumab Immunotherapy Treatment for Mesothelioma
COA Position Statement on Telehealth in Cancer Care Post-COVID-19
FDA Approves Two Liquid Biopsy Companion Diagnostics for Osimertinib
CMS Releases RO Model Final Rule
